UCB S. A.

UCB S. A.

UCB S. A.

Overview
Date Founded

1928

Headquarters

C/O UCB INC 1950 LAKE PARK DRIVE SMYRNA GA 30080

Type of Company

Public

Employees (Worldwide)

7,478

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Biotechnology

Company Description

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Executives & Employees

Chief Executive Officer & Chairman of the Executive Committee

Executive Vice President Chief Financial Officer

Chief Operating Officer

Executive Vice President Chief Operating Officer

Executive Vice President Chief Marketing Officer

Executive Vice President Chief Scientific Officer

Executive Vice President New Medicines Head & Chief Scientific Officer

Chief Medical Officer & Head, Development & Medical Practices

Chief Talent Officer

Chief Strategy Officer & Executive Vice President

Board of Directors

Former Professional at UCB S. A.

Vice Chairman at UCB Pharma SA - Belgium

Former Senior Partner at McKinsey & Co., Inc. (Belgium)

Former President & Chief Executive Officer at H. Lundbeck A/S

Founder at IDS Capital SA

Former Chief Executive Officer & Chairman of the Executive Committee at UCB S. A.

Professional at OxStem Ltd.

Head at Nikita SPRL

Member-Strategic Board at NeoMedLight SAS

Director-Health Research Strategy at World Health Organization /Europe

Paths to UCB S. A.
Potential Connections via
Relationship Science
You
UCB S. A.
Owners & Shareholders
Details Hidden

Wellington is an active manager which invests across a range of equity, fixed-income, commodities, alternative and other investment classes following a variety of strategies. Portfolio managers are responsible for both research and investment decisions within their territory, supported by proprietary research which is shared throughout the Wellington group. Their focus is primarily on the UK, Europe, the Middle East and Africa.The firm's proprietary research is the foundation for their investment approach, and is used by specialized teams to invest according to their specific strategies, which combine fundamental research with quantitative valuation techniques. Risk management combines proprietary models and external systems to ensure that portfolios are constructed in line with client risk tolerance.Global industry, regional and macroeconomic experts support both equity and fixed-income investments. Quantitative, technical, style and specialty research teams also contribute to the equity investment processes. Credit, sovereign, quantitative and sector-based analysts support fixed-income investing, working as teams to ensure that bottom-up decisions include relevant top-down factors, and vice versa.Wellington's multi-sector portfolios are regional and multi-currency. They cover the duration spectrum from money market and short bond to intermediate and market duration, core, and core bond plus portfolios. The firm also invests in specific sectors including high yield, corporate, mortgage-backed, emerging markets, and municipal bonds.

Details Hidden

ABL is a research-driven, GARP-oriented manager which utilizes a bottom-up stock selection approach and performs fundamental research, seeking to invest in companies with sustainable fundamental growth and attractive valuation. Their portfolios are actively traded to capitalize on the volatility in individual stocks and the overall market.The firm offers a comprehensive range of investment services across regions and along the risk-and-return spectrum including style-pure growth equities and value equities, style blend equities, fixed-income, index and structured services, alternative investments and customized and packaged multiasset-class solutions.

Details Hidden

Zadig Asset Management LLP (ZAM) is an independent hedge fund company based in London, UK. The firm was established in 2005 by Laurent Saglio to manage the Zadig Fund, a hedge fund for private individuals and institutions now closed to new investors.Before founding ZAM, Laurent Saglio participated in the creation of Voltaire Asset Management in 1998, which was closed in 2005 after the retirement of Ivan Briery, the firm's other founding partner.

Recent Transactions
Details Hidden

UCB S. A. purchases Element Genomics, Inc.

Details Hidden

UCB S. A. purchases Beryllium Discovery Corp.

Details Hidden

Amphastar Pharmaceuticals, Inc., Amphastar (United Kingdom) Ltd. purchase International Medication Systems (United kingdom) Ltd. from UCB S. A.

Transaction Advisors
Accountant

Advised onUCB S. A. purchases Solutia, Inc. /Resins Additives & Adhesives Businesses from Solutia, Inc.

Investment Advisor

Advised onUCB S. A. purchases UCB Pharma GmbH

Legal Advisor

Advised onUCB S. A. purchases Beryllium Discovery Corp.

Associate

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Legal Advisor

Advised onCytec Industries, Inc. purchases UCB SA /Surface Specialty Business from UCB S. A.

Legal Advisor

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Advisors & Consultants
Legal Advisor

Former Partner at Bondurant Mixson & Elmore LLP

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Clients

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Key Stats and Financials As of 2017
Market Capitalization
$13.3B
Total Enterprise Value
$12.8B
Earnings Per Share
$3.99
Revenue
$4.53B
Three Year Compounded Annual Growth Rate Of Revenue
10.65%
Five Year Compounded Annual Growth Rate Of Revenue
5.52%
Net Profit
$752M
EBITDAMargin
30.04%
Enterprise Value Sales
2.82x
Enterprise Value EBITDAOperating
9.38x
TEVNet Income
16.97x
Debt TEV
0.12x
EBITDA
$1.36B
Total Debt
$1.57B
Total Equity
$5.74B
Investments
Details Hidden

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Details Hidden

Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer's disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.

Details Hidden

Lumos Pharma, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Suppliers
Evotec AG Pharmaceuticals | Hamburg, HA

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Nektar Therapeutics Pharmaceuticals | San Francisco, CA

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Five Prime Therapeutics, Inc. Medical Support Services | South San Francisco, CA

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.